Literature DB >> 30677446

Germline variation in O6-methylguanine-DNA methyltransferase (MGMT) as cause of hereditary colorectal cancer.

Sami Belhadj1, Cátia Moutinho2, Pilar Mur3, Fernando Setien2, Pere Llinàs-Arias4, Montserrat Pérez-Salvia2, Tirso Pons5, Marta Pineda3, Joan Brunet6, Matilde Navarro3, Gabriel Capellá3, Manel Esteller7, Laura Valle8.   

Abstract

Somatic epigenetic inactivation of the DNA repair protein O6-methylguanine DNA methyltransferase (MGMT) is frequent in colorectal cancer (CRC); however, its involvement in CRC predisposition remains unexplored. We assessed the role and relevance of MGMT germline mutations and epimutations in familial and early-onset CRC. Mutation and promoter methylation screenings were performed in 473 familial and/or early-onset mismatch repair-proficient nonpolyposis CRC cases. No constitutional MGMT inactivation by promoter methylation was observed. Of six rare heterozygous germline variants identified, c.346C > T (p.H116Y) and c.476G > A (p.R159Q), detected in three and one families respectively, affected highly conserved residues and showed segregation with cancer in available family members. In vitro, neither p.H116Y nor p.R159Q caused statistically significant reduction of MGMT repair activity. No evidence of somatic second hits was found in the studied tumors. Case-control data showed over-representation of c.346C > T (p.H116Y) in familial CRC compared to controls, but no overall association of MGMT mutations with CRC predisposition. In conclusion, germline mutations and constitutional epimutations in MGMT are not major players in hereditary CRC. Nevertheless, the over-representation of c.346C > T (p.H116Y) in our familial CRC cohort warrants further research.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer genetics; Epimutation; Hereditary cancer; MGMT; Promoter hypermethylation

Year:  2019        PMID: 30677446     DOI: 10.1016/j.canlet.2019.01.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Systematic analysis using a bioinformatics strategy identifies SFTA1P and LINC00519 as potential prognostic biomarkers for lung squamous cell carcinoma.

Authors:  Yu-Zhen Yin; Shi-Hua Yao; Chun-Guang Li; Yu-Shui Ma; Zhou-Jun Kang; Jia-Jia Zhang; Cheng-You Jia; Li-Kun Hou; Shan-Shan Qin; Xin Fan; Han Zhang; Meng-Die Yang; Dan-Dan Zhang; Gai-Xia Lu; Hui-Min Wang; Li-Peng Gu; Lin-Lin Tian; Pei-Yao Wang; Ping-Sheng Cao; Wei Wu; Zi-Yang Cao; Zhong-Wei Lv; Bo-Wen Shi; Chun-Yan Wu; Geng-Xi Jiang; Da Fu; Fei Yu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 2.  Basic approaches, challenges and opportunities for the discovery of small molecule anti-tumor drugs.

Authors:  Yu-Shui Ma; Ji-Bin Liu; Xiao-Li Yang; Rui Xin; Yi Shi; Dan-Dan Zhang; Hui-Min Wang; Pei-Yao Wang; Qin-Lu Lin; Wen Li; Da Fu
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

3.  Novel methylation gene panel in adjacent normal tissues predicts poor prognosis of colorectal cancer in Taiwan.

Authors:  Chih-Hsiung Hsu; Cheng-Wen Hsiao; Chien-An Sun; Wen-Chih Wu; Tsan Yang; Je-Ming Hu; Chi-Hua Huang; Yu-Chan Liao; Chao-Yang Chen; Fu-Huang Lin; Yu-Ching Chou
Journal:  World J Gastroenterol       Date:  2020-01-14       Impact factor: 5.742

4.  Targeting Colorectal Cancer Stem Cells as an Effective Treatment for Colorectal Cancer.

Authors:  Yu-Shui Ma; Wen Li; Yu Liu; Yi Shi; Qin-Lu Lin; Da Fu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 5.  Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis.

Authors:  Laura Casalino; Pasquale Verde
Journal:  Genes (Basel)       Date:  2020-08-12       Impact factor: 4.096

6.  Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control.

Authors:  Ting-Miao Wu; Ji-Bin Liu; Yu Liu; Yi Shi; Wen Li; Gao-Ren Wang; Yu-Shui Ma; Da Fu
Journal:  Cancer Control       Date:  2020 Jul-Aug       Impact factor: 3.302

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.